

Description of Supplementary Files

File Name: Peer Review File

File Name: Supplementary Information

Description: Supplementary Figures, Supplementary Table, Supplementary References.

File Name: Supplementary Data 1

Description: Expression of 73 ETV2 target genes in 4 populations from SGET cell differentiation

File Name: Supplementary Data 2

Description: Transcriptome analysis of ES cell mesoderm differentiation and hemangiogenesis

File Name: Supplementary Data 3

Description: "pr"-enriched genes in Goode's data

File Name: Supplementary Data 4

Description: "dp"-enriched genes in Goode's data

File Name: Supplementary Data 5

Description: Transcription-related genes for comparison

File Name: Supplementary Data 6

Description: All the reads counting data for screen

File Name: Supplementary Data 7

Description: Genes important for ES cell viability or maintenance

File Name: Supplementary Data 8

Description: Genes implicated in mesoderm differentiation

File Name: Supplementary Data 9

Description: CRISPR screen for genes implicated in Etv2^{high} cell generation and chosen candidates

File Name: Supplementary Data 10


Description: 215 genes that are expressed in mesoderm and rank in top500 for depletion from pr cells to Etv2^{high} cells

File Name: Supplementary Data 11


Description: RNA-seq data for Δ Foxh1-pr cell

File Name: Supplementary Data 12


Description: Transcription-related genes for all samples including Δ Foxh1-pr cell



Supplementary Figure 1. Threshold of Etv2 in activating hemangiogenic genes (related to Figure 1) (a) Dynamics of Etv2-tdTomato and Scl-GFP expression in SGET ES cell differentiation (D0-3.75) was examined by flow cytometry. (b) Flow cytometry analysis of D4 EBs of wild type (wt) and Etv2-het(erozygote) SGET ES cell clones. (c) Dynamics of CD41 and TIE2 expression in comparison to Etv2-tdTomato and Scl-GFP expression in D4-6 SGET EBs is shown. (d) Expression of TIE2, another ETV2 target gene, is dependent on *Etv2* threshold expression. Flow cytometry analysis of Etv2-mCherry and TIE2 of D3.5 iEtv2-mCherry EBs differentiated in serum free conditions. -DOX, no DOX control; +DOX, DOX was added at 2 μ g/mL from D2.5-3.5. (e) Relative Etv2 mRNA levels in Etv2-mCherry^{hi}Scl-GFP⁻ and Etv2-tdTomato^{hi}Scl-GFP⁻ cells (marked as colored populations in boxes) sorted from D3.5 iEtv2-mCherry EBs and D4 SGET EBs, respectively. DOX (2 μ g/mL) was added from D2.5-3.5 for Etv2-mCherry induction. Error bars are s.d..




Supplementary Figure 2 Developmental route of *Etv2^{hi}* hemangiogenic progenitors (related to Figure 2) (a) Scheme of the TGET reporter ES cell line. (b) Sorted PDGFR α single positive cells from D3.5 TGET EBs were reseeded onto OP9 stromal cells and cultured for additional 4 days, and subjected to flow cytometry analysis for CD41 and FLK1. (c) Transcriptomes of "pr", "dp", and "endo_d6" cells was compared to those of 11 tandem regions along the primitive streak of E7.0 mouse gastrulating embryo, using Zipcode mapping¹. The bars show the Spearman rank correlation coefficients between the transcriptomes of "pr", "dp", or "endo_d6" vs. a specific region of primitive streak (see Supplementary Methods). Endo_d6, ES cell-derived D6 endoderm differentiation cells, was used as a control, which showed closer correlation to the distal regions of the primitive streak. (d) Expression patterns of "pr" (left, Group III in Fig. 2h and Supplementary Table 2) and "dp" (right, Group IV in Fig. 2h and Supplementary Table 2)-enriched genes in a published RNA-seq analysis of mesoderm differentiating ES cells². (e) Spearman's rank correlation of transcription factor and transcription-related gene expression among indicated samples.




Supplementary Figure 3. CRISPR screening identifies key *Etv2* upstream signals (related to Figure 3) (a) Functional

annotation of pathways with genes depleted from ES cells to PDGFR α ⁺ cells. (b) Scheme of the lentiviral construct expressing sgRNA and BFP used for validation of chosen candidates. (c) An example used for a candidate sgRNA validation: BFP⁻ (non sgRNA-expressing) or BFP⁺ (sgRNA-expressing) cells were used to compare the ratio of *Etv2*^{high} to PDGFR α ⁺. Cells successfully infected with the lentivirus expressing sgRNA against a specific gene simultaneously express the blue fluorescent protein BFP, which can be identified by flow cytometry.



Supplementary Figure 4. Foxh1 is required for FLK1⁺ mesoderm generation (related to Figure 4) (a) Scheme of the *iFoxh1-ΔFoxh1* ES cell line. (b) FLK1⁺ cells can be rescued by exogenous *Foxh1* expression from Δ *Foxh1* ES cells. *iFoxh1-ΔFoxh1* ES cells were differentiated in the presence or absence of DOX and analyzed for PDGFR α and FLK1 on D3. DOX was added at the beginning of differentiation at 500ng/mL. (right) The percentage of PDGFR α +FLK1⁻ ("pr"), PDGFR α +FLK1⁺ ("dp") and PDGFR α -FLK1⁺ ("fl") generated in the presence or absence of DOX is shown. (c) *iFoxh1*-wt ES cells were differentiated with different concentrations of DOX (added on D0), and FLK1⁺ (including "dp" and "fl") cells were analyzed on D3. The percentage of FLK1⁺ cells generated at different concentrations of DOX is shown. (d) (top) Bar graphs showing log₂-transformed fold changes of "pr" (Group III in Fig. 2h)-enriched genes in RNA-seq data (Δ *Foxh1*-pr vs. wt-pr); (bottom) log₂-transformed fold changes of "dp" (Group IV in Fig. 2h)-enriched genes in RNA-seq data (Δ *Foxh1*-pr vs. wt-dp). (e) x-axis showing the gene's correlation score to *T* for gastrulation initiation in early embryo, y-axis showing the gene's fold change comparing RNA-seq RPKMs of Δ *Foxh1*-pr cells to that of wt-pr cells. Downregulated genes in Δ *Foxh1*-pr cells were shown in yellow, otherwise in black. *, P-value<0.05 in Student's t-Test, **, P<0.01, ***, P<0.001, and n=3. Error bars are s.d..



Supplementary Figure 5. VEGF signaling is essential for *Etv2* threshold expression (related to Figure 6) (a) Flow

cytometry analysis of D4 wt SGET EB cells infected with lentivirus that expresses BFP and sgRNA against *Flk1*. The

percentage of Scl-GFP⁺ cells within BFP⁻ (wt) and BFP⁺ (Δ *Flk1*) cells is shown on the right. (b) Flow cytometry analysis of Etv2-

tdTomato and FLK1 expression in D5 wt and Δ *Vegfa* SGET EB cells in serum free conditions supplemented with BMP4

(5ng/mL). (c) Flow cytometry analysis for Etv2-tdTomato and Scl-GFP of D5 Δ *Vegfa* SGET EB cells differentiated in serum free

conditions supplemented with BMP4 (5ng/mL) and \pm VEGF-A (25ng/mL) from the beginning of differentiation. *, P-value<0.05

in Student's t-Test, n=3. Error bars are s.d..

Supplementary References

1. Peng, G., *et al.* Spatial Transcriptome for the Molecular Annotation of Lineage Fates and Cell Identity in Mid-gastrula Mouse Embryo. *Dev Cell* **36**, 681-697 (2016).
2. Goode, D.K., *et al.* Dynamic Gene Regulatory Networks Drive Hematopoietic Specification and Differentiation. *Dev Cell* **36**, 572-587 (2016).

Supplementary Table 1. A list of primers and sgRNAs used in this work

sgRNAs	Etv2 tdTomato knockin	ttttattggccttctgcacc	primers for Etv2-tdTomato knockin clone identification	Upstream of 5'-arm	ACAAGCTGACAGGACTGG
	Foxh1 knockout	cttatggaagcaccgattag		Inside tdTomato	TGGTGTAGTCCTCGTTGTGG
	Flk1 knockout	gtcccggtagcagcacttgt		Inside PGK-Hyg cassette	CACGATTGTCATGCCACGC
	Vegfa knockout	ttctcgctccgtagtagccg		Downstream of 3'-arm	CACGCACTGTGGAAACAAGGAC
	Etv2 single allele knockout/het	atcacaccaatgaacgtaga			
			primers for RT-qPCR	Eomes-f	GGCCCCTATGGCTCAAATTCC
				Eomes-r	CCTGCCCTGTTTGGTGATG
				Ets1-f	ACAGACTACTTTTCGGATCAAGCA
				Ets1-r	ACGCTCTCAAAGAGTCCTGG
				Etv2-f	ACAGCTACATTTTCAAGGCC
				Etv2-r	GTCCGAGGTGTTGCATCCC
				Evx1-f	GAGTACCAGCACAGCAAAGC
				Evx1-r	CTGCCACCGTTACTCTTGGG
				Flk1-f	TCCATCTTTTGGTGGAATGA
				Flk1-r	CTGGAGTACACGGTGGTGTC
				Foxa2-f	CCCTACGCCAACATGAACTCG
				Foxa2-r	GTTCTGCCGGTAGAAAGGGA
				Foxh1-f	TTATCCGTCAGGTCCAGGCA
				Foxh1-r	TCAGCAGGAATCAGGCTCAC
				Frzb-f	CACAGCACCCAGGCTAACG
				Frzb-r	TGCGTACATTGCACAGAGGAA
				Gsc-f	CAGATGCTGCCCTACATGAAC
				Gsc-r	TCTGGGTACTTCGTCTCCTGG
				Hand1-f	GGCAGCTACGCACATCATCA
				Hand1-r	CCTGGCATCGGGACCATAG
				Lmo1-f	GAGGCTTTTTGGCACCACAG
				Lmo1-r	TCTCTGATTGCAGAGCTGGC
				Med4-f	TGGAGGTCTTGTGAGGGAA
				Med4-r	CTTGGAAGTCCCCATCTCGG
				Mesp1-f	GTCCTCGGTCCTGGTTTAAG
				Mesp1-r	ACGATGGGTCCCACGATTCT
				Mixl1-f	ACGCAGTGCTTTCAAACC
				Mixl1-r	CCCXCAAGTGGATGTCTGG
				Oct4-f	AGTGGGGCGGTTTTGAGTAA
				Oct4-r	GGTGTACCCAAGGTGATCC
				Pbx3-f	GGACATCGGCGACATCCTC
				Pbx3-r	CGCCGGTTTTATTCTGTGAC
				Scl-f	GGGCTTTTGGCGATAGGTC
				Scl-r	GGAATCTCCACACCAGACAG
				Six2-f	AGGCCAAGGAAAGGGAGAAC
				Six2-r	GAACTGCCTAGCACCGACTT
				Smad1-f	GCTTCGTGAAGGGTTGGGG
				Smad1-r	CGGATGAAATAGGATTGTGGGG
				T/Brachyury-f	GGTCTCGGGAAAGCAGTGGC
				T/Brachyury-r	CATGTACTCTTTCTTGCTGG
				Tbx3-f	GAACCTACCTGTTCCCGGAAA
				Tbx3-r	CAATGCCCAATGTCTCGAAAAC
				Tlx2-f	CAACCTCTCAGGCTTGACC
				Tlx2-r	TCTGATCGATGCCGAAGCTG
				Trib1-f	TCCGAAGCCTCCTAAGACGA
				Trib1-r	GTCAACATAGCCCGTTCCA
			Vax1-f	CCAGGGTCTCGAAGAACGC	
			Vax1-r	ACAATCTTCCGAAGCGCCAG	
			Zcchc12-f	TGCCTTGAAACTGCGCTAT	
			Zcchc12-r	CTTACAACCAGCTGCACCA	